Therapeutic Effect of Dapagliflozin Combined With CSII on Newly Diagnosed Type 2 Diabetes Mellitus

Sponsor
Nanjing First Hospital, Nanjing Medical University
Study ID
NCT04120623
Phase
PHASE4
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • Dapagliflozin 10 MG — DRUG
    Dapagliflozin 10 MG combined with Insulin Aspart infused by continuous subcutaneous insulin infusion ( CSII).
  • Insulin Aspart — DRUG
    Insulin Aspart is infused through continuous subcutaneous insulin infusion ( CSII)

Study Details

To compare the effect of dapagliflozin combined with CSII and CSII alone on glucose profile in newly diagnosed type 2 diabetes mellitus by continuous glucose monitoring system.

Key Dates

Start date
Oct 1, 2019
Status verified
Sep 2019
Primary completion
Dec 31, 2019
Completion
Feb 28, 2020

Study Design

Enrollment
100 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Dapagliflozin combined with CSII
    Dapagliflozin 10MG combined with Aspart infused by CSII as glucose lowering therapy.
  • Active Comparator: CSII alone
    Aspart infused by CSII alone as glucose lowering therapy.

Primary Outcome Measure

the effect of dapagliflozin combined with CSII on glucose profile [ Time Frame: 5 weeks ]

Central Contacts

Related Studies